The InviScreen® AMR Gene Panel is a qualitative molecular research assay for the detection of selected antimicrobial resistance-associated gene targets in purified DNA. Using Loop-mediated Isothermal Amplification (LAMP) on the InviDx® System, the assay supports rapid AMR research and surveillance across human, animal, food and environmental One Health settings.
The InviScreen® AMR Gene Panel detects the following AMR gene classes and targets:
By detecting these AMR gene classes, the InviScreen® AMR Gene Panel provides broad coverage of approximately 200 resistance-gene variants across human, veterinary, food and environmental settings.
The kit can be used in combination with the InviScreen® UTI Pathogen Panel to identify AMR genes in pathogens associated with urinary tract infections (UTI) in urine samples. DNA isolates of other human, animal or environmental sample types may be analysed in the context of One Health surveillance. Learn more about One Health surveillance.
The assay workflow is designed for near-sample and decentralized molecular testing environments. Positive and negative controls are included to monitor assay validity and help identify potential run failures.
For Research Use Only (RUO). Intended for use by trained personnel.
| Specifications | |
|---|---|
| Contents | 8 x 12-well reaction strips containing lyophilized reaction mixes |
| Specimen type | DNA isolates of various sample types |
| Sample Preparation | DNA must be extracted using a method appropriate for the respective source matrix. A total of 25-75 µL purified DNA is required per sample. For urine-derived DNA, the extraction workflow provided with the InviScreen® UTI Pathogen Panel may be used where appropriate. Users should verify the suitability of alternative sample-preparation workflows for their intended research application. |
| Panel targets |
dfrA12, dfrA14, dfrA17, fosA5, fosA6, blaTEM, blaSHV, blaCTX-M-1, blaCTX-M-2, blaCTX-M-9, blaKPC, blaGES, blaOXA-48, qnrB1, qnrB3, qnrB5, qnrB6, vanA, mecA, blaVIM, blaNDM, blaIMP-22, mcr-1, mcr-9, mcr-10
|
| Internal controls | Included |
| Turnaround time | 45 min |
| No. of tests | 8 |
| Technology | Isothermal amplification (LAMP) |
| Instrument compatibility | InviDx® Instrument |
| Certification | RUO |
08 SEP 2026
| Product Name | Package Size | Catalogue No. |
|---|---|---|
| InviScreen® AMR Gene Panel | 8 samples | 3010010299 |
The InviScreen® AMR Gene Panel is a molecular assay for the qualitative detection of clinically relevant antimicrobial resistance (AMR) genes in DNA isolated from various sample types. The assay is designed for use with the InviDx® instrument and supports rapid, decentralized AMR screening.
The InviScreen® AMR Gene Panel detects clinically relevant target genes from the following AMR groups:
| ANTIBIOTIC CLASS | AMR GROUP | TARGET GENE(S) |
|---|---|---|
| Trimethoprim / antifolates | dfrA (trimethoprim resistance) | dfrA12, dfrA14, dfrA17 |
| Fosfomycin | fosA (fosfomycin resistance) | fosA5, fosA6 |
| β-lactams | TEM/SHV β-lactamases; some variants are extended-spectrum β-lactamases (ESBLs) | blaTEM, blaSHV |
| Extended-spectrum β-lactams | CTX-M ESBL groups | blaCTX-M-1, blaCTX-M-2, blaCTX-M-9 |
| Carbapenems and other β-lactams | Class A and Class D serine carbapenemases | blaKPC, blaGES, blaOXA-48 |
| Fluoroquinolones | qnrB (plasmid-mediated quinolone resistance) | qnrB1, qnrB3, qnrB5, qnrB6 |
| Glycopeptides | vanA (vancomycin resistance) | vanA |
| β-lactams: anti-staphylococcal penicillins and cephalosporins | mecA (methicillin resistance) | mecA |
| Carbapenems and other β-lactams | MBL (Class B metallo-β-lactamases) | blaVIM, blaNDM, blaIMP-22 |
| Polymyxins | mcr (mobile/plasmid-mediated colistin resistance) | mcr-1, mcr-9, mcr-10 |
By detecting these AMR targets, the InviScreen® AMR Gene Panel provides broad coverage of approximately 200 resistance-gene variants carrying these resistance genes.
The assay uses qualitative Loop-mediated Isothermal Amplification (LAMP) to detect the AMR gene targets. LAMP is an isothermal nucleic acid amplification technology. Amplification is performed on the compatible InviDx® instrument.
The assay provides AMR gene detection in approximately 45 minutes on the InviDx® instrument. Following amplification, results are automatically interpreted using the InviDx® Hub.
The InviDx® Hub is the software platform used for automated result interpretation.
It applies AI-based, assay-specific analysis to data generated by the InviDx® instrument and supports standardized result reporting.
The InviScreen® AMR Gene Panel is designed for use with the InviDx® instrument. Result interpretation is performed using the associated InviDx® Hub.
Yes. The InviScreen® AMR Gene Panel can be used in combination with the InviScreen® UTI Pathogen Panel. The InviScreen® UTI Pathogen Panel includes a dedicated sample extraction workflow. The DNA extracted during this workflow can subsequently be tested with both the InviScreen® UTI Pathogen Panel and the InviScreen® AMR Gene Panel.
Using both panels can support the detection of urinary tract infection-associated pathogens and selected antimicrobial resistance genes from the same extracted DNA sample. The two panels are separately available products.
The InviScreen® AMR Gene Panel detects selected antimicrobial resistance gene targets. It is not designed to identify specific pathogens.
For urinary tract infection testing, the AMR Gene Panel can be used together with the InviScreen® UTI Pathogen Panel, which detects UTI-associated pathogens.
The kit is designed for the analysis of any previously isolated DNA in liquid format. DNA from various human, animal or environmental sample types can be analysed, supporting a broad range of One Health surveillance applications.
For each AMR detection run of 12 reactions (10x AMR gene targets, 1x positive control and 1x negative control) only 25 µl of DNA solution are required.
Yes. The InviScreen® AMR Gene Panel is designed for near-sample and decentralized molecular testing environments using the InviDx® instrument.
Its rapid workflow and reagent format support flexible use outside centralized laboratory settings, including human health, veterinary and environmental surveillance applications.
.
Yes. The InviScreen® AMR Gene Panel can support One Health surveillance across human, animal and environmental settings.
The assay enables the detection of selected AMR gene targets together covering approximately 200 resistance-gene variants [OH5.1]in DNA isolations from various sample types.
Learn more about One Health surveillance.
Yes. Positive and negative controls are included in the assay. The controls help monitor assay validity and identify potential run failures.
The assay detects selected genes associated with antimicrobial resistance. A detected AMR gene may be associated with resistance to a specific antimicrobial class. However, results should be interpreted together with the relevant organism, clinical or surveillance context and other laboratory findings.
No. A negative result means that the AMR gene targets included in the panel were not detected. A negative result does not exclude resistance caused by other genes, mutations, resistance mechanisms or targets that are not included in the panel.
No. The assay detects the presence of selected AMR gene targets and does not directly measure phenotypic antimicrobial susceptibility. Additional laboratory testing may be required to characterize antimicrobial susceptibility or confirm the clinical significance of a result.
The InviScreen® AMR Gene Panel is for Research Use Only (RUO).
The assay is intended for use by trained personnel. It is not intended for human diagnostic procedures.
.jpeg)
Search